Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)”

24 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 24 results

Early research (Phase 1)Looking for participantsNCT06690827
What this trial is testing

Clinical Trial of CD123-targeted CAR-NK Therapy for Relapse/refractory AML or BPDCN

Who this might be right for
AML (Acute Myeloid Leukemia)BPDCN (blastic Plasmacytoid Dendritic Cell Neoplasm)
Chongqing Precision Biotech Co., Ltd 30
Early research (Phase 1)Study completedNCT02730312
What this trial is testing

PH 1 Study to Evaluate Safety and Tolerability of XmAb14045 in Patients With CD123-expressing Hematologic Malignancies

Who this might be right for
Acute Myelogenous LeukemiaB-cell Acute Lymphoblastic LeukemiaBlastic Plasmacytoid Dendritic Cell Neoplasm+1 more
Xencor, Inc. 120
Testing effectiveness (Phase 2)Active Not RecruitingNCT03599960
What this trial is testing

Combination Chemotherapy in Patients With Newly Diagnosed BPDCN

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Centre Hospitalier Universitaire de Besancon 26
Not applicableEnded earlyNCT05645744
What this trial is testing

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Chronic Lymphocytic Leukemia in RelapseSmall Lymphocytic Lymphoma, Relapsed+8 more
Mustang Bio 3
Not applicableLooking for participantsNCT05430971
What this trial is testing

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) International Registry

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Immune Oncology Research Institute 200
Early research (Phase 1)Study completedNCT03485547
What this trial is testing

Study of Venetoclax, a BCL2 Antagonist, for Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm
Dana-Farber Cancer Institute 5
Early research (Phase 1)Looking for participantsNCT05476770
What this trial is testing

Tagraxofusp in Pediatric Patients With Relapsed or Refractory CD123 Expressing Hematologic Malignancies

Who this might be right for
Hematologic MalignancyAMLALL+8 more
Therapeutic Advances in Childhood Leukemia Consortium 54
Very early researchLooking for participantsNCT06765876
What this trial is testing

CART123 T Cells in Relapsed or Refractory CD123+ Hematologic Malignancies: A Dose Escalation Phase I Trial

Who this might be right for
Leukemia, Myeloid, Acute(AML)Precursor Cell Lymphoblastic Leukemia-LymphomaMyelodysplastic Syndromes (MDS)+1 more
Institute of Hematology and Blood Transfusion, Czech Republic 18
Testing effectiveness (Phase 2)Ended earlyNCT04342962
What this trial is testing

Tagraxofusp in Patients With CD123+ or With BPDCN-IPh-like Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 25
Early research (Phase 1)Active Not RecruitingNCT06325748
What this trial is testing

SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS

Who this might be right for
AML/MDSCD33 Expressing Hematological MalignanciesFLT3 Expressing Hematological Malignancies
Senti Biosciences 21
Testing effectiveness (Phase 2)Active Not RecruitingNCT03386513
What this trial is testing

Study of IMGN632 in Patients With Untreated BPDCN and Relapsed/Refractory BPDCN

Who this might be right for
Blastic Plasmacytoid Dendritic Cell NeoplasmMyeloproliferative Neoplasm
AbbVie 179
Not applicableStudy completedNCT02859623
What this trial is testing

Descriptive Study of the Efficacy of Treatments for Blastic Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Blastic Plasmacytoid Dendritic Cell NeoplasmHematological Malignancies
Centre Hospitalier Universitaire de Besancon 86
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07007052
What this trial is testing

Phase II Study Evaluating the Efficacy and Safety of the Combination of Tagraxofusp and Venetoclax in Treatment-naive Blastic Plasmacytoid Dendritic Cell Neoplasm Patients

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
French Innovative Leukemia Organisation 33
Early research (Phase 1)Active Not RecruitingNCT04013685
What this trial is testing

Precision-T: A Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphoid LeukemiaMyelodysplastic Syndromes+3 more
Orca Biosystems, Inc. 255
Testing effectiveness (Phase 2)Ended earlyNCT04317781
What this trial is testing

Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center 3
Testing effectiveness (Phase 2)Ended earlyNCT05086315
What this trial is testing

First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Who this might be right for
Acute Lymphocytic LeukaemiaAcute Myeloid Leukaemia RefractoryMyelodysplastic Syndromes+1 more
Sanofi 101
Early research (Phase 1)Ended earlyNCT03203369
What this trial is testing

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Cellectis S.A. 1
Testing effectiveness (Phase 2)Ended earlyNCT04109482
What this trial is testing

Trial to Evaluate the Safety and Efficacy of MB-102 in Patients With BPDCN.

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Mustang Bio 3
Testing effectiveness (Phase 2)Study completedNCT02113982
What this trial is testing

Tagraxofusp in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)Acute Myeloid Leukemia (AML)
Stemline Therapeutics, Inc. 138
Testing effectiveness (Phase 2)Looking for participantsNCT04216524
What this trial is testing

Venetoclax, SL-401, and Chemotherapy for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm

Who this might be right for
Blastic Plasmacytoid Dendritic Cell Neoplasm
M.D. Anderson Cancer Center 40
Load More Results